KRON - Kronos ends development of larnarplenib combo therapy for AML
2023-12-18 17:22:17 ET
More on Kronos Bio
- Kronos to cut 19% of workforce, focus on drugs KB-0742, lanraplenib
- Kronos Bio stock slightly up on positive preliminary data for investigational cancer drug
- Seeking Alpha’s Quant Rating on Kronos Bio
- Historical earnings data for Kronos Bio
- Financial information for Kronos Bio
For further details see:
Kronos ends development of larnarplenib combo therapy for AML